Magnesium Trisilicate Alginic Acid Antacid Foam Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antacid medications for hyperacidity and associated stomach issues often cause side effects such as constipation, aluminum intoxication, hypercalcaemia, and metabolic alkalosis, and do not provide long-term protection to the affected tissue.
Innovation Solution
A pharmaceutical composition combining magnesium trisilicate as a gastric acid-binding agent with alginic acid or its salts and optionally vegetable or essential oils, forming a viscous foam barrier that reduces gastroesophageal reflux and neutralizes excess gastric acid without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If traditional antacids (aluminum hydroxide, magnesium hydroxide, calcium carbonate) are used to neutralize gastric acid, then acid neutralization is achieved, but side effects such as constipation, aluminum intoxication, hypercalcaemia, and metabolic alkalosis occur
Solution Approach 1:
The patent extracts and eliminates the harmful components (aluminum, excessive magnesium, calcium) from traditional antacid formulations, retaining only magnesium trisilicate in controlled amounts combined with alginic acid, thereby removing the sources of aluminum intoxication, hypercalcaemia, and severe constipation while maintaining acid-neutralizing capability
Solution Approach 2:
The patent creates a composite material system combining magnesium trisilicate (antacid component) with alginic acid (mucus-forming component) in specific ratios, where the two materials work synergistically to provide acid neutralization without the harmful side effects of traditional single-component antacids
2Object-affected harmful factors
If aluminum-containing antacids are used to neutralize stomach acid, then acid neutralization is effective, but constipation and aluminum intoxication occur
Solution Approach 1:
The patent completely removes aluminum from the formulation, eliminating the source of aluminum intoxication and constipation associated with aluminum-containing antacids, while maintaining effective acid neutralization through magnesium trisilicate
3Object-affected harmful factors
If calcium-based antacids are used to neutralize gastric acid, then acid neutralization is achieved, but hypercalcaemia, alkalosis, and kidney failure risk increase
Solution Approach 1:
The patent removes calcium from the antacid formulation, eliminating the risk of hypercalcaemia, metabolic alkalosis, and milk-alkaline syndrome associated with calcium-based antacids, while maintaining therapeutic effectiveness through magnesium trisilicate
4Object-affected harmful factors
If sodium bicarbonate is used to neutralize stomach acid, then rapid acid neutralization occurs, but metabolic alkalosis, high sodium load, and gastric rupture risk occur
Solution Approach 1:
The patent eliminates sodium bicarbonate from the formulation, removing the sources of metabolic alkalosis, excessive sodium load, and gastric rupture risk, while maintaining effective acid neutralization through the slower-acting but safer magnesium trisilicate
Solution Approach 2:
The patent changes the reaction kinetics parameter by using magnesium trisilicate instead of rapid-acting sodium bicarbonate, achieving a slower, more controlled acid neutralization that prevents gastric rupture while avoiding metabolic alkalosis through the absence of sodium and bicarbonate
5Object-affected harmful factors
If proton pump blockers or H2 receptor antagonists are used to treat severe hyperacidity, then acid production is reduced, but serious side effects including headache, diarrhea, myopathies, and hepatitis occur
Solution Approach 1:
The patent uses locally acting, short-duration antacid materials (magnesium trisilicate and alginic acid) that neutralize acid at the site of action without systemic absorption, avoiding the serious systemic side effects of proton pump blockers and H2 receptor antagonists while providing sufficient symptom relief
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively treats hyperacidity and its sequelae with minimal side effects, providing a long-lasting therapeutic effect by forming a pH-neutral foam barrier that protects the esophagus and neutralizes gastric acid, while preventing constipation and other adverse effects associated with traditional antacids.
Implementation Method 1
forming a viscous foam barrier that reduces gastroesophageal reflux
Implementation Method 2
forming a viscous foam barrier
Implementation Method 3
magnesium trisilicate on the one hand together with alginic acid... neutralizes gastric acid
Data Source
AI summary
The invention relates to a pharmaceutical composition, in particular an antacid, which is in a solid or liquid dosage form and comprises, in in each case pharmaceutically effective amounts, a combination of at least one active ingredient which neutralizes and/or binds gastric acid together with alginic acid and/or an alginic acid salt. The pharmaceutical composition is suitable in particular for the prophylactic and/or curative treatment of hyperacidity and thus related consequential symptoms and disorders, in particular heartburn, oesophagitis, dyspeptic complaints, dyspepsia, gastritis, ulcer diseases and the like.